Merck
CN
所有图片(1)

文件

S8626

Sigma-Aldrich

磺胺嘧啶

99.0-101.0%

登录查看公司和协议定价
所有图片(1)
别名:
N-2-嘧啶基-4-氨基苯磺酰胺, N1-(嘧啶-2-基)磺胺
经验公式（希尔记法）:
C10H10N4O2S
CAS号:
68-35-9
分子量:
250.28
Beilstein:
6733588
EC 号:
200-685-8
MDL编号:
MFCD00006065
PubChem化学物质编号:
24899802
NACRES:
NA.85

描述

Solubility - Practically insoluble in water, slightly soluble in acetone, very slightly soluble in ethanol (96 per cent). It dissolves in solutions of alkali hydroxides and in dilute mineral acids.

质量水平

200

检测方案

99.0-101.0%

形式

powder or crystals

颜色

white to faint yellow, faint pink

mp

253 °C (dec.) (lit.)

溶解性

96% ethanol: very slightly soluble
acetone: slightly soluble
water: practically insoluble

抗生素抗菌谱

Gram-negative bacteria
Gram-positive bacteria
mycoplasma

作用机制

DNA synthesis | interferes
enzyme | inhibits

SMILES string

Nc1ccc(cc1)S(=O)(=O)Nc2ncccn2

InChI

1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)

InChI key

SEEPANYCNGTZFQ-UHFFFAOYSA-N

正在寻找类似产品? Visit 产品对比指南

相关类别

一般描述

化学结构式：磺酰胺

应用

磺胺嘧啶是一种短效磺胺类药物，常用于与乙胺嘧啶合用治疗获得性免疫缺陷综合征患者的弓形虫病。也用于治疗新生儿先天性感染 。在研究再活化弓形虫病的鼠模型时，磺胺嘧啶已被用于控制急性感染 。

生化/生理作用

磺胺嘧啶是一种磺胺类抗生素，通过抑制二氢喋呤合成酶而阻断二氢叶酸的合成。磺胺嘧啶是细菌合成叶酸所需的对氨基苯甲酸 (PABA) 的竞争性抑制剂 。对革兰氏阳性菌、革兰氏阴性菌和衣原体有效。耐药模式是通过改变二氢喋呤合成酶或叶酸合成的替代途径。

其他说明

将容器密闭保存在干燥和通风良好的地方。储存类别 (TRGS 510)：非易燃固体

警示用语：

Warning

危险分类

Acute Tox. 4 Oral - Aquatic Chronic 2 - Repr. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 2

个人防护装备

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

为方便起见，与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码？

在网站页面上，产品编号会附带包装尺寸/数量一起显示（例如：T1503-25G）。请确保 在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503
货号
-
25G
包装规格/数量

其它示例：

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题？欢迎随时联系我们技术服务 寻求帮助

批号可以在产品标签上"批“ （Lot或Batch）字后面找到。

Aldrich 产品

  • 如果您查询到的批号为 TO09019TO 等，请输入去除前两位字母的批号：09019TO。

  • 如果您查询到的批号含有填充代码（例如05427ES-021），请输入去除填充代码-021的批号：05427ES。

  • 如果您查询到的批号含有填充代码（例如 STBB0728K9），请输入去除填充代码K9的批号：STBB0728。

未找到您寻找的产品？

部分情况下，可能未在线提供COA。如果搜索不到COA，可在线索取。

索取COA

Romain Sonneville et al.
Neurology, 79(17), 1762-1766 (2012-10-12)
Cerebral toxoplasmosis remains a common neurologic complication in patients with AIDS. In this study, we aimed to characterize the prognosis of patients with HIV infection with severe forms of cerebral toxoplasmosis and to investigate the effects of adjunctive steroids on
Sven Jechalke et al.
Applied and environmental microbiology, 79(5), 1704-1711 (2013-01-15)
Spreading manure containing antibiotics in agriculture is assumed to stimulate the dissemination of antibiotic resistance in soil bacterial populations. Plant roots influencing the soil environment and its microflora by exudation of growth substrates might considerably increase this effect. In this
Ildiko R Dunay et al.
Antimicrobial agents and chemotherapy, 53(10), 4450-4456 (2009-07-29)
Immunocompromised patients are at risk of developing toxoplasmosis, and although chemotherapy is available, standard treatments are often complicated by severe side effects. Artemisinin is a new highly potent antimalarial drug that has activity against Toxoplasma gondii in vitro. However, artemisinin
Tamim M Niazi et al.
International journal of radiation oncology, biology, physics, 84(3), e305-e310 (2012-06-02)
For patients with anal canal and advanced rectal cancer, chemoradiation therapy is a curative modality or an important adjunct to surgery. Nearly all patients treated with chemoradiation experience some degree of radiation-induced dermatitis (RID). Prevention and effective treatment of RID
Pascale Meneceur et al.
Antimicrobial agents and chemotherapy, 52(4), 1269-1277 (2008-01-24)
Sulfadiazine, pyrimethamine, and atovaquone are widely used for the treatment of severe toxoplasmosis. Their in vitro activities have been almost exclusively demonstrated on laboratory strains belonging to genotype I. We determined the in vitro activities of these drugs against 17
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门